CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of proposed changes to the Local Coverage…

Read MoreCareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection

CAS and Molecule.one Announce Strategic Collaboration to Accelerate Drug Discovery

 CAS is the American Chemical Society’s specialized division for scientific information solutions and Molecule.one is the Leading company in biotechnology. The two institutions have entered into a strategic collaboration focused on the joint development of computer-aided synthetic design techniques to accelerate…

Read MoreCAS and Molecule.one Announce Strategic Collaboration to Accelerate Drug Discovery

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which…

Read MoreAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Marinus…

Read MoreMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement…

Read MoreHDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused…

Read MoreU.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older